Radiation Oncologist Speaks to AI Potential in the Cancer Space

News
Video

Richard Bakst, MD, speaks to the potential use of artificial intelligence in the radiation oncology space, and how he hopes to see it evolve.

In the field of radiation oncology, artificial intelligence (AI) has emerged as a transformative force, that can help to redefine diagnostic and therapeutic approaches. In an interview with CancerNetwork®, Richard Bakst, MD, discussed the impact of AI in radiology, and how it has the potential to enhance patient care and medical practices.

Bakst, a radiation oncologist at Mount Sinai, highlighted AI's influence in diagnostic radiology, particularly in screening for lung cancer and assisting in demographic interpretations. He also mentioned AI's budding role in therapeutic radiology; its ability to detect microscopic disease on imaging scans and assist in contouring normal structures shows promise for optimizing treatment planning.

Looking toward the future, Bakst believes AI will become a valuable tool in radiotherapy, influencing volume design, assessing the risk of microscopic disease, and aiding in tumor volume elimination. This integration of AI is expected to significantly enhance the precision and effectiveness of cancer treatment.

With AI's ability to detect subtle abnormalities, optimize treatment planning, and enhance targeting precision, it is poised to influence the radiology space.

Transcript:

[AI] is taking a role in all spaces. It has a huge footprint in diagnostic radiology, screening for lung cancer, and assisting in demographic reads; [it has] a very strong foothold in the diagnostic space. It’s going to make its way into therapy space, and it already has in some instances in terms of our workflow. We have the ability to use AI to detect microscopic disease on our scans. [This helps] think about contouring normal structures. It will penetrate the therapeutic planning for radiotherapy. Definitely in the very short term, hopefully it will influence our volume design, assess the risk of microscopic disease, and help eliminate tumor volumes. It’s coming. It will enhance our ability to target cancer, risk stratify patients, and determine appropriate volumes.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.